Elena Vasilevna Volchkova

Elena Vasilevna Volchkova

Auto-generated profile, based on publicly available information

Elena Vasilevna Volchkova

I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DKDmitry Kostyushev
Dmitry Kostyushev
AKAnastasiya Kostyusheva
Anastasiya Kostyusheva
SBSergey Brezgin
Sergey Brezgin
VSValery Smirnov
Valery Smirnov
EVElena Volchkova
Elena Volchkova
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
CRISPR/Cas technologies have advanced dramatically in recent years. Many different systems with new properties have been characterized and a plethora of hybrid CRISPR/Cas systems able to modify the epigenome, regulate transcription, and correct mutations in DNA and RNA have been devised. However, practical application of CRISPR/Cas systems is severely limited by the lack of effective delivery tools. In this review, recent advances in developing vehicles for the delivery of CRISPR/Cas in the form of ribonucleoprotein complexes are outlined. Most importantly, we emphasize the use of extracellular vesicles (EVs) for CRISPR/Cas delivery and describe their unique properties: biocompatibility, safety, capacity for rational design, and ability to cross biological barriers. Available molecular tools that enable loading of desired protein and/or RNA cargo into the vesicles in a controllable manner and shape the surface of EVs for targeted delivery into specific tissues (e.g., using targeting ligands, peptides, or nanobodies) are discussed. Opportunities for both endogenous (intracellular production of CRISPR/Cas) and exogenous (post-production) loading of EVs are presented.

31 October 2019 in Viruses
Verified
Journal Article
Open access
PDF file
AKAnastasiya Kostyusheva
Anastasiya Kostyusheva
SBSergey Brezgin
Sergey Brezgin
EBEkaterina Bayurova
Ekaterina Bayurova
IGIlya Gordeychuk
Ilya Gordeychuk
MIMaria Isaguliants
Maria Isaguliants
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
Chronic hepatitis B virus infection (CHB) caused by the hepatitis B virus (HBV) is one of the most common viral infections in the world. Reactivation of HBV infection is a life-threatening condition observed in patients with CHB receiving chemotherapy or other medications. Although HBV reactivation is commonly attributed to immune suppression, other factors have long been suspected to play a role, including intracellular signaling activated in response to DNA damage. We investigated the effects of DNA-damaging factors (doxorubicin and hydrogen peroxide) on HBV reactivation/replication and the consequent DNA-damage response. Dose-dependent activation of HBV replication was observed in response to doxorubicin and hydrogen peroxide which was associated with a marked elevation in the mRNA levels of ataxia-telangiectasia mutated (ATM) and ATM- and RAD3-related (ATR) kinases. Downregulation of ATM or ATR expression by shRNAs substantially reduced the levels of HBV RNAs and DNA. In contrast, transcriptional activation of ATM or ATR using CRISPRa significantly increased HBV replication. We conclude that ATM and ATR are essential for HBV replication. Furthermore, DNA damage leading to the activation of ATM and ATR transcription, results in the reactivation of HBV replication.

1 January 2018 in Infekcionnye bolezni
Verified
Journal Article
Closed access
NPN.N. Pimenov
N.N. Pimenov
SKS.V. Komarova
S.V. Komarova
IKI.V. Karandashova
I.V. Karandashova
NTN.N. Tsapkova
N.N. Tsapkova
EVE.V. Volchkova
E.V. Volchkova
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov

15 July 2021 in Viruses
Verified
Journal Article
Open access
PDF file
SBSergey Brezgin
Sergey Brezgin
AKAnastasiya Kostyusheva
Anastasiya Kostyusheva
EBEkaterina Bayurova
Ekaterina Bayurova
EVElena Volchkova
Elena Volchkova
VGVladimir Gegechkori
Vladimir Gegechkori
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
Viral infections cause a variety of acute and chronic human diseases, sometimes resulting in small local outbreaks, or in some cases spreading across the globe and leading to global pandemics. Understanding and exploiting virus–host interactions is instrumental for identifying host factors involved in viral replication, developing effective antiviral agents, and mitigating the severity of virus-borne infectious diseases. The diversity of CRISPR systems and CRISPR-based tools enables the specific modulation of innate immune responses and has contributed impressively to the fields of virology and immunology in a very short time. In this review, we describe the most recent advances in the use of CRISPR systems for basic and translational studies of virus–host interactions.

11 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
AKAnastasiya Kostyusheva
Anastasiya Kostyusheva
SBSergey Brezgin
Sergey Brezgin
NPNatalia Ponomareva
Natalia Ponomareva
VGVladimir Gegechkori
Vladimir Gegechkori
DKDmitry Kostyushev
Dmitry Kostyushev
CRISPR/Cas is a powerful tool for studying the role of genes in viral infections. The invention of CRISPR screening technologies has made it possible to untangle complex interactions between the host and viral agents. Moreover, whole-genome and pathway-specific CRISPR screens have facilitated identification of novel drug candidates for treating viral infections. In this review, we highlight recent developments in the fields of CRISPR/Cas with a focus on the use of CRISPR screens for studying viral infections and identifying new candidate genes to aid development of antivirals.

1 March 2019 in Molecular Biology
Verified
Journal Article
Closed access
PDF file
AKA. P. Kostyusheva
A. P. Kostyusheva
DKDmitry Kostyushev
Dmitry Kostyushev
SBSergey Brezgin
Sergey Brezgin
DZD. N. Zarifyan
D. N. Zarifyan
EVE. V. Volchkova
E. V. Volchkova
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
The CRISPR/Cas9 nuclease system can effectively suppress the replication of the hepatitis B virus (HBV), while covalently closed circular DNA (cccDNA), a highly resistant form of the virus,...